NASDAQ : KPTI
Karyopharm Therapeutics Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 0.8798 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 19.96M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 15.02M |
| Enterprise Value | 278.44M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 22.68M |
| Shares Outstanding | 22.68M |
| Shares Change (YoY) | +129.56% |
| Shares Change (QoQ) | +17.09% |
| Owned by Insiders (%) | 2.86% |
| Owned by Institutions (%) | 83.15% |
| Float | 18.59M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.10 |
| Forward PS | 0.11 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 1.90 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 0.79 |
| Quick Ratio | 0.71 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1.67 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -47.61% |
| Return on Invested Capital (ROIC) | -437.05% |
| Return on Capital Employed (ROCE) | 359.36% |
| Weighted Average Cost of Capital (WACC) | 11.78% |
| Revenue Per Employee | $643,075 |
| Profits Per Employee | -$985,702 |
| Employee Count | 228 |
| Asset Turnover | 1.36 |
| Inventory Turnover | 0.31 |
Taxes
| Measure | Value |
|---|
| Income Tax | -32,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.04 |
| 52-Week Price Change | -89.11% |
| 50-Day Moving Average | 1.22 |
| 200-Day Moving Average | 6.04 |
| Relative Strength Index (RSI) | 42.99 |
| Average Volume (20 Days) | 4,784,155 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 7.27M |
| Short Previous Month | 6.06M |
| Short % of Shares Out | 32.04% |
| Short % of Float | 39.08% |
| Short Ratio (days to cover) | 5.19 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 146.62M |
| Gross Profit | 145.25M |
| Operating Income | -82.35M |
| Pretax Income | -224.77M |
| Net Income | -224.74M |
| EBITDA | -82.20M |
| EBIT | -82.35M |
| Loss Per Share | -$11.58 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 65.11M |
| Total Debt | 328.53M |
| Net Cash | -263.43M |
| Net Cash Per Share | -$11.61 |
| Equity (Book Value) | -330.17M |
| Book Value Per Share | -14.56 |
| Working Capital | -27.86M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -65.35M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 149,000 |
| Net Borrowing | 27.00M |
| Free Cash Flow | -65.35M |
| FCF Per Share | -$2.88 |
Margins
| Measure | Value |
|---|
| Gross Margin | 99.06% |
| Operating Margin | -56.17% |
| Pretax Margin | -153.30% |
| Profit Margin | -153.28% |
| EBITDA Margin | -56.06% |
| EBIT Margin | -56.17% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -129.56% |
| Shareholder Yield | -129.56% |
| Earnings Yield | -1,749.47% |
| FCF Yield | -435.21% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $7.25 |
| Price Target Difference | 995.17% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 31.52% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Feb 26, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:15 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -24.52 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |